BETTY DOBBS: Open Payments
NPI 1558022665 · ACKERMAN, MS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$690 in 43 payments from 8 companies in 2025. Trend: 2023 $0 · 2024 $0 · 2025 $690
Food & beverage: $690
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 21 | $192 |
| Otsuka America Pharmaceutical, Inc. | 6 | $151 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 5 | $92 |
| Axsome Therapeutics, Inc. | 3 | $79 |
| Vanda Pharmaceuticals Inc. | 3 | $67 |
| E.R. Squibb & Sons, L.L.C. | 2 | $51 |
| Supernus Pharmaceuticals, Inc. | 2 | $40 |
| Janssen Pharmaceuticals, Inc | 1 | $19 |
Products named: VRAYLAR, REXULTI, CAPLYTA, Auvelity, FANAPT, COBENFY, Qelbree, SPRAVATO.
Industry payments across MS — which companies pay providers there.
